Investment Analysts’ Recent Ratings Changes for Elevance Health (ELV)

Elevance Health (NYSE: ELV) has recently received a number of price target changes and ratings updates:

• 11/11/2026 – Elevance Health had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 11/7/2026 – Elevance Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/27/2026 – Elevance Health had its price target raised by Wells Fargo & Company from $473.00 to $492.00. They now have an “overweight” rating on the stock.
• 10/23/2026 – Elevance Health was given a new $490.00 price target by Mizuho.
• 10/23/2026 – Elevance Health had its “neutral” rating reaffirmed by The Goldman Sachs Group. They now have a $451.00 price target on the stock.
• 10/23/2026 – Elevance Health had its price target raised by TD Cowen from $465.00 to $495.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by UBS Group from $460.00 to $523.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Royal Bank Of Canada from $424.00 to $455.00. They now have a “sector perform” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Guggenheim from $460.00 to $485.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Barclays from $469.00 to $472.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Morgan Stanley from $404.00 to $449.00. They now have an “equal weight” rating on the stock.
• 10/22/2026 – Elevance Health had its price target raised by Robert W. Baird from $393.00 to $406.00. They now have a “neutral” rating on the stock.
• 10/12/2026 – Elevance Health had its price target raised by Guggenheim from $455.00 to $460.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Elevance Health had its price target raised by Barclays from $457.00 to $469.00. They now have an “overweight” rating on the stock.

Elevance Health Stock Performance

ELV traded up $0.88 on Thursday, reaching $430.36. 467,728 shares of the stock were exchanged, compared to its average volume of 1,584,433. The company’s 50-day moving average price is $414.63 and its 200 day moving average price is $374.40. Elevance Health, Inc. has a fifty-two week low of $274.84 and a fifty-two week high of $450.69. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. The firm has a market capitalization of $92.98 billion, a PE ratio of 18.35, a PEG ratio of 2.05 and a beta of 0.63.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The business had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. During the same quarter in the previous year, the business earned $6.03 EPS. The company’s quarterly revenue was up .7% compared to the same quarter last year. As a group, sell-side analysts forecast that Elevance Health, Inc. will post 29.15 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s payout ratio is currently 29.34%.

Insiders Place Their Bets

In other Elevance Health news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the sale, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This trade represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.34% of the company’s stock.

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.